Niagen Bioscience (NAGE) Insider Shahbazi Buys 31,746 Shares
Hamed Shahbazi purchased 31,746 shares of Niagen Bioscience on June 24, 2026, as part of a broader insider buying trend.
Reviewed by automated data checks against the source filing. How we make and check alerts
Hamed Shahbazi bought 31,746 shares of Niagen Bioscience, Inc. ($NAGE) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NAGE is down 3.5% after 1 week, down 7.0% after 1 month and down 27.8% to date (from the $3.45 close on Jun 24, 2026).
NAGE
Niagen Bioscience, Inc.
Key Points
- Hamed Shahbazi bought 31,746 shares of Niagen Bioscience (NAGE) on June 24, 2026, at a price of $3.42 per share, totaling approximately $108,000.
- This purchase comes as Niagen Bioscience has a market cap of about $240.5 million and is trading above its 52-week low of $2.87.
- The company, focused on developing products for healthy aging, is set to report earnings on November 3, 2026.
Get $NAGE trade alerts by text
We text you when insiders, Congress or big funds trade $NAGE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Niagen Bioscience, Inc. alert may contain errors. Disclosures
Hamed Shahbazi's Recent Purchase
On June 24, 2026, Hamed Shahbazi bought 31,746 shares of Niagen Bioscience, Inc. (NAGE) on the NasdaqCM. The shares were purchased at a price of $3.42 each, bringing the total value of the transaction to about $108,000. This move reflects a growing trend among insiders at Niagen as they show confidence in the company's future.
A Surge in Insider Activity
Shahbazi's purchase aligns with similar transactions by other insiders on the same day. Yu Wing Tak Wendy, Steven Rubin, Kristin Patrick, Ann Cohen, Ng Wang Yu Gary, and Jaksch Frank Jr. each acquired 31,746 shares. This coordinated buying effort indicates a strong belief in Niagen's prospects, as multiple insiders made the same investment.
Niagen's Market Position
Niagen Bioscience is currently trading at $3.42, which is above its 52-week low of $2.87 but well below its high of $10.52. The stock's current price is near its 50-day moving average of $3.19, suggesting it is experiencing some stability. The company's market capitalization stands at approximately $240.5 million, highlighting its position in the consumer defensive sector, specifically in packaged foods.
What NAGE Does
Niagen Bioscience, Inc. develops products aimed at promoting healthy aging. The company offers dietary supplements containing proprietary ingredients and has a presence in various sales channels, including e-commerce platforms and specialty retailers. This insider buying could be seen as a positive sign as Niagen prepares for its next earnings report.
What's Ahead for NAGE
The next earnings report for Niagen Bioscience is scheduled for November 3, 2026. As the company works towards this event, the recent insider transactions may reflect a commitment to its growth and potential in the marketplace. Keep in mind that these filings reflect past holdings and may not represent current positions.
Related Filing Alerts
Source: Hamed Shahbazi's Form 4 filing on $NAGE (Jun 24, 2026). Find the original filing: NAGE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts